Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04194892 · ClinicalTrials.gov registry record · Phase 1

A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy Participants

A Phase 1 study of Healthy, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 1
Development phase
12
Enrollment target
1
Study location

NCT04194892: Completed Phase 1 study of Healthy, sponsored by Eli Lilly and Company.

NCT04194892 is a Phase 1 study of Healthy that has completed, run by Eli Lilly and Company. The registered enrollment target is 12 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04194892, a Phase 1 study of Healthy, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 1
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to assess how fast pegilodecakin gets into the blood stream and how long it takes the body to remove it, when given as a solution formulation via a prefilled syringe (PFS) versus from a vial drawn into a conventional syringe. Information about side effects will be collected. The study is open to healthy participants. Total participant duration in trial is approximately 42 days.

Primary Outcome

Pharmacokinetic (PK): maximum drug concentration (Cmax) of Pegilodecakin.

Conditions Studied

Healthy

Interventions

  • BIOLOGICAL Pegilodecakin

Study Locations (1)

Texas

  • PPD Phase 1 Clinic - Austin

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2018-01-19
Est. Completion 2018-03-14
Phase Phase 1
Eli Lilly and Company

1,341 total trials

What the finished NCT04194892 record still lists

NCT04194892 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which Pegilodecakin is the first listed.

NCT04194892 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT04194892 about?

NCT04194892 is a clinical study titled "A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy Participants". The purpose of this study is to assess how fast pegilodecakin gets into the blood stream and how long it takes the body to remove it, when given as a solution formulation via a prefilled syringe (PFS) versus from a vial drawn into a conventional syringe. Information about side effects will be collec...

What is the current status of trial NCT04194892?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2018-01-19. Estimated completion is 2018-03-14.

What conditions does trial NCT04194892 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT04194892?

The interventions under investigation include: Pegilodecakin (BIOLOGICAL).

Who is sponsoring clinical trial NCT04194892?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04194892 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04194892's enrollment target sits among peer trials

12 996th of 1090 higher than 61 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04194892, the US trial registry maintained by the National Library of Medicine. NCT04194892 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.